Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries.
暂无分享,去创建一个
Prabhat Jha | Dorairaj Prabhakaran | Gregory Brill | William H Shrank | Rajeev Gupta | D. Prabhakaran | Rajeev Gupta | P. Jha | W. Shrank | N. Choudhry | G. Brill | Niteesh K Choudhry | Jennifer M Polinski | J. Polinski | Sagar Dugani | Christina E Stark | S. Dugani
[1] A. Karan,et al. Why Publicly-Financed Health Insurance Schemes Are Ineffective in Providing Financial Risk Protection , 2012 .
[2] R Brian Haynes,et al. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. , 2007, Archives of internal medicine.
[3] D. Prabhakaran,et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. , 2013, JAMA.
[4] D. Chokshi,et al. Leveraging university research to advance global health. , 2007, JAMA.
[5] T. Greenhalgh. DRUG MARKETING IN THE THIRD WORLD: BENEATH THE COSMETIC REFORMS , 1986, The Lancet.
[6] N J Wald,et al. A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.
[7] Alan D. Lopez,et al. Fatal and Nonfatal Cardiovascular Disease and the Use of Therapies for Secondary Prevention in a Rural Region of India , 2009, Circulation.
[8] J. Tu,et al. Use of ezetimibe in the United States and Canada. , 2008, The New England journal of medicine.
[9] Thomas H. Lee. Eulogy for a quality measure. , 2007, The New England journal of medicine.
[10] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.
[11] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[12] N. Roy,et al. The Medical Council of India guidelines on industry-physician relationship: breaking the conspiracy of silence. , 2010, The National medical journal of India.
[13] S. Yusuf,et al. Epidemiology and causation of coronary heart disease and stroke in India , 2007, Heart.
[14] A. Kotwani,et al. A comparative evaluation of price and quality of some branded versus branded–generic medicines of the same manufacturer in India , 2011, Indian journal of pharmacology.
[15] S. Yusuf,et al. The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study , 2009, Nature Clinical Practice Cardiovascular Medicine.
[16] T. Gaziano,et al. Cardiovascular Disease in the Developing World and Its Cost-Effective Management , 2005, Circulation.
[17] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[18] William H Shrank,et al. Four-dollar generics--increased accessibility, impaired quality assurance. , 2010, The New England journal of medicine.
[19] Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data , 2009 .
[20] B. J. Gersh. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980–2000 , 2008 .
[21] L S Geiss,et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. , 2001, Diabetes care.
[22] A. Kesselheim,et al. The International Pharmaceutical Market as a Source of Low-Cost Prescription Drugs for U.S. Patients , 2008, Annals of Internal Medicine.
[23] R. Goyal,et al. A Review Article on Prescription Behavior of Doctors, Influenced By The Medical Representative In Rajasthan, India , 2013 .
[24] C. S. Gautam,et al. Spurious and counterfeit drugs: a growing industry in the developing world , 2009, Postgraduate Medical Journal.
[25] R. Bansal,et al. Unethical relationship between doctors and drugs companies , 2005 .
[26] G. Mudur. India’s capping of drug prices will leave drugs costing near the market price , 2012, BMJ : British Medical Journal.
[27] J. Gagne,et al. How many "me-too" drugs is too many? , 2011, JAMA.
[28] D. Wald,et al. Randomized Polypill Crossover Trial in People Aged 50 and Over , 2012, PloS one.
[29] M. Stedman,et al. A Systematic Review of Adherence to Cardiovascular Medications in Resource-Limited Settings , 2011, Journal of General Internal Medicine.
[30] Luni Chen,et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.
[31] S. Pai,et al. Drug promotional practices in Mumbai: a qualitative study. , 2007, Indian journal of medical ethics.
[32] M. Datta,et al. Treatment‐Seeking Behavior and Compliance of Diabetic Patients in a Rural Area of South India , 2002, Annals of the New York Academy of Sciences.
[33] T. Dilip. On Publicly-Financed Health Insurance Schemes Is the Analysis Premature? , 2012 .
[34] Vikram Patel,et al. Chronic diseases and injuries in India , 2011, The Lancet.
[35] S. Yusuf,et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.
[36] M Alan Brookhart,et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.
[37] Gretchen A. Stevens,et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participants , 2011, The Lancet.
[38] N. Choudhry. Improving the pathway from cardiovascular medication prescribing to longer-term adherence: new results about old issues. , 2010, Circulation. Cardiovascular quality and outcomes.
[39] S. Yusuf,et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial , 2009, The Lancet.
[40] D. Jamison,et al. Financing health improvements in India. , 2008, Health affairs.
[41] Martin O'Flaherty,et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. , 2010, JAMA.
[42] R. Lodha,et al. Financial incentives and the prescription of newer vaccines by doctors in India. , 2010, Indian journal of medical ethics.
[43] Rajeev Gupta,et al. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India , 2009, Vascular health and risk management.
[44] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.